Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

10.1200/JCO.20.02060

Saved in:
Bibliographic Details
Main Authors: Dimopoulos, Meletios A, Spicka, Ivan, Quach, Hang, Oriol, Albert, Hajek, Roman, Garg, Mamta, Beksac, Meral, Bringhen, Sara, Katodritou, Eirini, Chng, Wee-Joo, Leleu, Xavier, Iida, Shinsuke, Mateos, Maria-Victoria, Morgan, Gareth, Vorog, Alexander, Labotka, Richard, Wang, Bingxia, Palumbo, Antonio, Lonial, Sagar
Other Authors: DEAN'S OFFICE (MEDICINE)
Format: Article
Language:English
Published: AMER SOC CLINICAL ONCOLOGY 2022
Subjects:
Science & Technology
Life Sciences & Biomedicine
Oncology
CONTINUOUS THERAPY
PLUS LENALIDOMIDE
FIXED DURATION
DOUBLE-BLIND
OPEN-LABEL
BORTEZOMIB
DEXAMETHASONE
OUTCOMES
DARATUMUMAB
PREDNISONE
Online Access:https://scholarbank.nus.edu.sg/handle/10635/229088
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Language: English

Internet

https://scholarbank.nus.edu.sg/handle/10635/229088

Similar Items